Hologic Inc. (NASDAQ:HOLX) has a beta of 1.27, a 12-month trailing P/E ratio of 17.26, and a growth ratio of 0.99. The stock’s Relative Strength Index (RSI) is 49.01, with weekly volatility at 2.60% and ATR at 2.06. The HOLX stock’s 52-week price range has touched low of $26.49 and a $77.49 high. Its shares traded lower over the last trading session, losing -2.93% on 12/29/20. The shares fell to a low of $72.49 before closing at $72.58. Intraday shares traded counted 1.19 million, which was 36.91% higher than its 30-day average trading volume of 1.88M. HOLX’s previous close was $74.77 while the outstanding shares total 259.91M.
Investors have identified the Medical Instruments & Supplies company Hologic Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $18.73 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Hologic Inc. (HOLX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For HOLX, the company has in raw cash 701.0 million on their books with 324.9 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 2.22 billion total, with 1.24 billion as their total liabilities.
HOLX were able to record 740.2 million as free cash flow during the Q4 2020 quarter of the year, this saw their quarterly net cash flow reduce by 99.2 million. In cash movements, the company had a total of 896.6 million as operating cash flow.
Potential earnings growth for Hologic Inc. (HOLX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the Q4 2020 quarter of the year, Hologic Inc. recorded a total of 1.35 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 35.72% coming in sequential stages and their sales for the Q4 2020 quarter increasing by 38.9%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 415.1 million trying to sell their products during the last quarter, with the result yielding a gross income of 931.8 million. This allows shareholders to hold on to 259.91M with the recently reported earning now reading 1.90 cents per share. This is a figure that compared to analyst’s prediction for their Q4 2020 (2.07 cents a share).
Having a look at the company’s valuation, the company is expected to record 4.49 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on HOLX sounds very interesting.
Is the stock of HOLX attractive?
In related news, Principal Accounting Officer, COHN BENJAMIN JORDAN sold 1,477 shares of the company’s stock in a transaction that recorded on Dec 10. The sale was performed at an average price of 73.64, for a total value of 108,759. As the sale deal closes, the Div. President, Diagnostics, Thornal Kevin R now sold 16,869 shares of the company’s stock, valued at 1,248,212. Also, General Counsel, Griffin John M. sold 22,900 shares of the company’s stock in a deal that was recorded on Nov 18. The shares were price at an average price of 71.08 per share, with a total market value of 1,627,689. Following this completion of acquisition, the Principal Accounting Officer, COHN BENJAMIN JORDAN now holds 5,000 shares of the company’s stock, valued at 362,900. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.10%.
11 out of 17 analysts covering the stock have rated it a Buy, while 4 have maintained a Hold recommendation on Hologic Inc.. 0 analysts has assigned a Sell rating on the HOLX stock. The 12-month mean consensus price target for the company’s shares has been set at $86.92.